Comparison of Clinical, Hematological and Biochemical Characteristics of Patients Suffering from Delta and Non-Delta Variant of COVID-19
DOI:
https://doi.org/10.51273/esc23.251921Keywords:
Severe cute respiratory syndrome Coronavirus 2, Coronavirus disease 2019,, Delta variant, Non-delta variantAbstract
Objective: To compare the clinical, hematological and biochemical characteristics of patients suffering from delta and non-delta variants of COVID-19.
Method: This cross-sectional study was conducted at Farooq Hospital Westwood Lahore during 1st March 2022 to 31st August 2022. After obtaining informed written consent, nasopharyngeal swabs and 5 ml of blood samples in both EDTA and clotted vacutainers of eighty two infected patients with COVID-19, who were admitted in COVID-19 unit, were collected. The viral nucleic acid was isolated from nasopharyngeal swabs by using a Qiagen nucleic acid extraction kit. RT-PCR was performed to detect the delta variant in COVID-19 infected patients by using SARS-CoV-2 Variant B.1.617 identification kit. Further hematological and
biochemical parameters were performed.
Results: We did a comparative analysis of clinical and laboratory characteristic of delta and non-delta COVID19 patients admitted in Farooq Hospital Westwood, confirmed by RT-PCR and found that patients presented with delta variant had more severe disease with significantly more cough, fever, shortness of breath and lower SpO2 at the presentation. The hematological and biochemical markers showed more lymphopenia, greater CRP,Interleukin 6,LDHand ferritin.Hospitalstay of delta variants ofCOVID-19 patients had longer duration as compared to the non-delta COVID-19 patients.
Conclusion: Delta COVID-19 had more severe disease with more dyspnea, hypoxia, hematological and biochemical parameters abnormalities compared to the non-delta COVID-19 patients. Patients suffering from delta variant of COVID-19 had greater length of hospital stay as compared to the non-delta variant of COVID-19 with more oxygen requirement and more mortality rate.
References
Jakovljevic M, Bjedov S, Jaksic N, Jakovljevic I. COVID-19 pandemia and public and global mental health from the perspective of global health security. Psychiatria Danubina. 2020;32(1):6-14.
Luo R, Delaunay‐Moisan A, Timmis K, Danchin A. SARS‐CoV‐2 biology and variants: anticipation of viral evolution and what needs to be done. Wiley Online Library; 2021. p. 2339-63.
Choi JY, Smith DM. SARS-CoV-2 variants of concern. Yonsei medical journal. 2021;62(11):961.
Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic. The Lancet. 2021;398(10317):2126-8.
Somerville M, Curran JA, Dol J, Boulos L, Saxinger L, Doroshenko A, et al. Public health implications of SARS-CoV-2 variants of concern: a rapid scoping review. BMJ open. 2021;11(12):e055781.
Tatsi E-B, Filippatos F, Michos A. SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence. Epidemiology and infection. 2021;149.
Chakraborty C, Sharma AR, Bhattacharya M, Agoramoorthy G, Lee S-S. A paradigm shift in the combination changes of SARS-CoV-2 variants and increased spread of delta variant (B. 1.617. 2) across the world. Aging and disease. 2022;13(3):927.
Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant. New England Journal of Medicine. 2021.
Basheer A, Zahoor I. Genomic epidemiology of SARS-CoV-2 divulge B. 1, B. 1.36, and B. 1.1. 7 as the most dominant lineages in first, second, and third wave of SARS-CoV-2 infections in Pakistan. Microorganisms. 2021;9(12):2609.
Hasan Z, Aamir UB, Nasir A, Kanji A, Samreen A, Bukhari AR, et al. Changing SARS-CoV-2 variants in Karachi, Pakistan from alpha to delta through COVID-19 waves three and four. 2021.
Hasan M, Gupta S. Wave-wise comparison of COVID 19 based on SARS-CoV-2 Variants of Concern (VOCs) in Bangladesh, India, Sri Lanka, Pakistan, Nepal and the probable reasons behind the less devastating effects of Delta variant in Bangladesh: a review: Brac University; 2022.
Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M, et al. SARS-CoV-2 spike mutations, L452R, T478K, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. Microorganisms. 2021;9(7):1542.
Kumar V, Singh J, Hasnain SE, Sundar D. Possible link between higher transmissibility of alpha, kappa and delta variants of SARS-CoV-2 and increased structural stability of its spike protein and hACE2 affinity. International journal of molecular sciences. 2021;22(17):9131.
O’Horo JC, Challener DW, Speicher L, Bosch W, Seville MT, Bierle DM, et al., editors. Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant. Mayo Clinic Proceedings; 2022: Elsevier.
Fall A, Eldesouki RE, Sachithanandham J, Morris CP, Norton JM, Gaston DC, et al. The displacement of the SARS-CoV-2 variant Delta with Omicron: An investigation of hospital admissions and upper respiratory viral loads. EBioMedicine. 2022;79:104008.
Venkatraja B, Srilakshminarayana G, Kumar BK. The dominance of severe acute respiratory syndrome coronavirus 2 B. 1.617 and its sublineages and associations with mortality during the COVID-19 pandemic in India between 2020 and 2021. The American journal of tropical medicine and hygiene. 2022;106(1):142.
Hakim MS, Wibawa H, Trisnawati I, Supriyati E, Khair RE, Iskandar K, et al. Association between prognostic factors and the outcomes of patients infected with SARS-CoV-2 harboring multiple spike protein mutations. Scientific Reports. 2021;11(1):1-24.
Tan BKJ, Han R, Zhao JJ, Tan NKW, Quah ESH, Tan CJ-W, et al. Prognosis and persistence of smell and taste dysfunction in patients with covid-19: meta-analysis with parametric cure modelling of recovery curves. bmj. 2022;378.
Shiehzadegan S, Alaghemand N, Fox M, Venketaraman V. Analysis of the delta variant B. 1.617. 2 COVID-19. Clinics and Practice. 2021;11(4):778-84.
Alexandar S, Ravisankar M, Kumar RS, Jakkan K. A comprehensive review on Covid-19 Delta variant. International Journal of Pharmacology and Clinical Research (IJPCR). 2021;5(83-85):7.
Thangaraj JWV, Yadav P, Kumar CG, Shete A, Nyayanit DA, Rani DS, et al. Predominance of delta variant among the COVID-19 vaccinated and unvaccinated individuals, India, May 2021. Journal of Infection. 2022;84(1):94-118.
Vaishya R, Sibal A, Sharma H, Singh SK. Lack of vaccination and associated comorbidities predispose to the need for intensive care in individuals infected with the delta variant–A case cohort study from a tertiary care hospital in New Delhi, India. Diabetes & metabolic syndrome. 2021;15(4):102203.
Huang I, Pranata R, Lim MA, Oehadian A, Alisjahbana B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Therapeutic advances in respiratory disease. 2020;14:1753466620937175.
Zhou B, She J, Wang Y, Ma X. Utility of ferritin, procalcitonin, and C-reactive protein in severe patients with 2019 novel coronavirus disease. 2020.
Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al. Association of inflammatory markers with the severity of COVID-19: a meta-analysis. International Journal of Infectious Diseases. 2020;96:467-74.
